Nabil Mohammad Azmi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nabil Mohammad Azmi has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Diana Melissa Dualim
8 shared publicationsZairul Azwan Mohd Azman
7 shared publicationsMohd Firdaus Mohd Hayati
4 shared publicationsIsmail Sagap
Department of Surgery, Hospital Canselor Tuanku Muhriz, Faculty of Medicine Universiti Kebangsaan Malaysia Kuala Lumpur Malaysia
3 shared publications- Muhammad Irfan Abdul Jalal
Affiliation UKM Medical Molecular Biology Institute (UMBI), Hospital Canselor Tuanku Muhriz (HCTM), Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia
3 shared publications Nur Afdzillah Abdul Rahman
Colorectal Unit Department of Surgery Faculty of Medicine The National University of Malaysia Kuala Lumpur Malaysia
3 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by Springer Nature in BMC Surgery
- Vol. 26 (1)
Patients recover while surgeons suffer: a narrative review on surgical ergonomics in laparoscopic surgery
- 1 August 2026
- Published by Springer Nature in BMC Surgery
- Vol. 26 (1)
Open AccessPatients recover while surgeons suffer: a narrative review on surgical ergonomics in laparoscopic surgery
- Open Access
- 24 June 2026
- Published by Korean Society of Coloproctology in Annals of Coloproctology
- Vol. 42 (3) , 381-382
Comments on “Long-term outcomes of intramural rectal botulinum toxin injections for urge fecal incontinence: a salvage therapy for sacral neuromodulation nonresponders?”
- 24 June 2026
- Published by Korean Society of Coloproctology in Annals of Coloproctology
- Vol. 42 (3) , 381-382
Open AccessComments on “Long-term outcomes of intramural rectal botulinum toxin injections for urge fecal incontinence: a salvage therapy for sacral neuromodulation nonresponders?”
- Open Access
- 27 April 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 999
Validation of Multi-Target Stool DNA Methylation Test for Colorectal Cancer Detection: A Preliminary Analysis
Colorectal cancer (CRC) develops gradually from precancerous adenomas and is highly curable when detected early. In Malaysia, however, most cases are diagnosed at advanced stages, leading to poorer outcomes despite the availability of screening programmes such as the immunological Faecal Occult Blood Test (iFOBT). Limited screening uptake and poor adherence contribute to delayed diagnosis. Therefore, effective non-invasive and patient-friendly screening tools are essential. Background/Objectives: This study aims to validate the diagnostic performance of the multi-target stool DNA (mt-sDNA) test. Methods: This cross-sectional validation study was conducted at the Endoscopic Center, Hospital Canselor Tuanku Muhriz (HCTM), from January 2024 to September 2025. Adults aged 18–75 years undergoing elective or emergency colonoscopy were included. Results: Among 246 patients, most were male (56.5%), Malay (65.2%), and aged 55–75 years (91.3%). CRC prevalence was 8.5%. A significant association was observed between age group and colonoscopy findings (p = 0.005), with older individuals more likely to have CRC or adenomatous lesions. Most CRC (90.4%) and advanced adenoma (84.6%) cases occurred in symptomatic patients; however, this difference did not demonstrate a significant association with colonoscopy outcomes (p = 0.069). Per rectal bleeding, constitutional symptoms, altered bowel habit, abdominal pain and constipation were significantly associated with CRC and adenomatous lesions. The mt-sDNA test showed a sensitivity of 63.2%, specificity of 85.0%, positive predictive value of 36.4%, and negative predictive value of 94.4%. Conclusions: Preliminary findings indicate that mt-sDNA demonstrates good specificity and high negative predictive value, but moderate sensitivity and low positive predictive value.
- 27 April 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 999
Open AccessValidation of Multi-Target Stool DNA Methylation Test for Colorectal Cancer Detection: A Preliminary Analysis
Colorectal cancer (CRC) develops gradually from precancerous adenomas and is highly curable when detected early. In Malaysia, however, most cases are diagnosed at advanced stages, leading to poorer outcomes despite the availability of screening programmes such as the immunological Faecal Occult Blood Test (iFOBT). Limited screening uptake and poor adherence contribute to delayed diagnosis. Therefore, effective non-invasive and patient-friendly screening tools are essential. Background/Objectives: This study aims to validate the diagnostic performance of the multi-target stool DNA (mt-sDNA) test. Methods: This cross-sectional validation study was conducted at the Endoscopic Center, Hospital Canselor Tuanku Muhriz (HCTM), from January 2024 to September 2025. Adults aged 18–75 years undergoing elective or emergency colonoscopy were included. Results: Among 246 patients, most were male (56.5%), Malay (65.2%), and aged 55–75 years (91.3%). CRC prevalence was 8.5%. A significant association was observed between age group and colonoscopy findings (p = 0.005), with older individuals more likely to have CRC or adenomatous lesions. Most CRC (90.4%) and advanced adenoma (84.6%) cases occurred in symptomatic patients; however, this difference did not demonstrate a significant association with colonoscopy outcomes (p = 0.069). Per rectal bleeding, constitutional symptoms, altered bowel habit, abdominal pain and constipation were significantly associated with CRC and adenomatous lesions. The mt-sDNA test showed a sensitivity of 63.2%, specificity of 85.0%, positive predictive value of 36.4%, and negative predictive value of 94.4%. Conclusions: Preliminary findings indicate that mt-sDNA demonstrates good specificity and high negative predictive value, but moderate sensitivity and low positive predictive value.
- 14 February 2026
- Published by Elsevier in Visual Journal of Emergency Medicine
- Vol. 42
Point-of-care-ultrasound (POCUS) in facilitating the diagnosis of gallstone ileus
- 14 February 2026
- Published by Elsevier in Visual Journal of Emergency Medicine
- Vol. 42
Point-of-care-ultrasound (POCUS) in facilitating the diagnosis of gallstone ileus
- 13 January 2026
- Published by Wiley in Asian Journal of Endoscopic Surgery
- Vol. 19 (1) , e70215
Comments on: Clinical Impacts of Minimally Invasive Transperineal Abdominoperineal Resection in Crohn's Disease
- 13 January 2026
- Published by Wiley in Asian Journal of Endoscopic Surgery
- Vol. 19 (1) , e70215
Comments on: Clinical Impacts of Minimally Invasive Transperineal Abdominoperineal Resection in Crohn's Disease
- Open Access
- 31 December 2025
- Published by Korean Society of Coloproctology in Annals of Coloproctology
- Vol. 41 (6) , 596-597
Comments on “Improved outcomes with cyanoacrylate glue for ileocolic anastomosis in right colectomy: a multicenter study”
- 31 December 2025
- Published by Korean Society of Coloproctology in Annals of Coloproctology
- Vol. 41 (6) , 596-597
Open AccessComments on “Improved outcomes with cyanoacrylate glue for ileocolic anastomosis in right colectomy: a multicenter study”
- 24 November 2025
- Published by Wiley in Surgical Practice
- Vol. 30 (3) , 194
Comments on ‘Five‐year outcome of laparoscopic transanal total mesorectal excision in a single centre’
- 24 November 2025
- Published by Wiley in Surgical Practice
- Vol. 30 (3) , 194
Comments on ‘Five‐year outcome of laparoscopic transanal total mesorectal excision in a single centre’
- 5 November 2025
- Published by Elsevier in Visual Journal of Emergency Medicine
- Vol. 41
A case of immunocompromised patient with horseshoe abscess
- 5 November 2025
- Published by Elsevier in Visual Journal of Emergency Medicine
- Vol. 41
A case of immunocompromised patient with horseshoe abscess
- 29 October 2025
- Published by SAGE Publications in Surgical Innovation
- Vol. 33 (2) , 196-197
Comments on: “Early Experience With a Novel Super-Hydrophilic Laparoscopic Scope Cleaning Device and Narrative Review of Available Cleaning Strategies”
- 29 October 2025
- Published by SAGE Publications in Surgical Innovation
- Vol. 33 (2) , 196-197
Comments on: “Early Experience With a Novel Super-Hydrophilic Laparoscopic Scope Cleaning Device and Narrative Review of Available Cleaning Strategies”
- Open Access
- 15 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0334349
A prospective single-masked, non-inferiority, parallel-group randomized controlled trial of the efficacy of a ChatGPT-based AI chatbot to improve Boston bowel preparation scores for colonoscopy preparation: A trial protocol
Artificial intelligence (AI) is transforming healthcare through tools like large language model chatbots. AI chatbots can simulate human conversation, provide personalized information, and interact with patients in real time. Their ease of use and conversational interface make them attractive for healthcare education, especially in resource-limited settings. We propose a prospective, single-masked, randomized controlled trial to evaluate whether an AI-based chatbot (ChatGPT) is non-inferior to standard counseling in terms of patients’ adherence to pre-colonoscopy bowel preparation instructions and thus enhance the Boston Bowel Preparation Score (BBPS). Patients undergoing colonoscopy (ntotal = 96) will be randomized to ChatGPT 4.0 Large Language Model (LLM)-aided Colonoscopy Counseling (NChatGPT = 48) or standard counseling (nsc = 48) arms at a 1:1 ratio using a central block randomization scheme of varying block sizes. In the first group, participants will interact with ChatGPT 4.0 for bowel preparation counseling before colonoscopy, whilst the second group will receive standard counseling from trained clinicians. Only the outcome assessors will be masked to the intervention allotment. The primary endpoint is the BBPS, assessed for non-inferiority. Secondary endpoints are patient anxiety (DASS-21) and patient satisfaction assessed using DASS-21 and PSQ-18 questionnaires, respectively and the findings will be reported descriptively with two-sided 95% confidence interval and any p-values will be considered exploratory without multiplicity adjustment. The primary endpoint data will be analyzed using the intention-to-treat (ITT) analysis and non-inferiority framework based on the analysis of covariance (ANCOVA) to control the confounders (age, gender (male as the risk factor), prior colonoscopy experience, colonoscopy indication, and baseline constipation score). The results will be compared with the findings based on the per-protocol (PP) analysis as part of the sensitivity analysis. The protocol adheres to SPIRIT 2025 and the SPIRIT-AI extension guidelines to ensure comprehensive reporting of this AI-based intervention. This trial has received ethics approval and the trial protocol has been registered with the clinicaltrials.gov registry (NCT06905782).
- 15 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0334349
Open AccessA prospective single-masked, non-inferiority, parallel-group randomized controlled trial of the efficacy of a ChatGPT-based AI chatbot to improve Boston bowel preparation scores for colonoscopy preparation: A trial protocol
Artificial intelligence (AI) is transforming healthcare through tools like large language model chatbots. AI chatbots can simulate human conversation, provide personalized information, and interact with patients in real time. Their ease of use and conversational interface make them attractive for healthcare education, especially in resource-limited settings. We propose a prospective, single-masked, randomized controlled trial to evaluate whether an AI-based chatbot (ChatGPT) is non-inferior to standard counseling in terms of patients’ adherence to pre-colonoscopy bowel preparation instructions and thus enhance the Boston Bowel Preparation Score (BBPS). Patients undergoing colonoscopy (ntotal = 96) will be randomized to ChatGPT 4.0 Large Language Model (LLM)-aided Colonoscopy Counseling (NChatGPT = 48) or standard counseling (nsc = 48) arms at a 1:1 ratio using a central block randomization scheme of varying block sizes. In the first group, participants will interact with ChatGPT 4.0 for bowel preparation counseling before colonoscopy, whilst the second group will receive standard counseling from trained clinicians. Only the outcome assessors will be masked to the intervention allotment. The primary endpoint is the BBPS, assessed for non-inferiority. Secondary endpoints are patient anxiety (DASS-21) and patient satisfaction assessed using DASS-21 and PSQ-18 questionnaires, respectively and the findings will be reported descriptively with two-sided 95% confidence interval and any p-values will be considered exploratory without multiplicity adjustment. The primary endpoint data will be analyzed using the intention-to-treat (ITT) analysis and non-inferiority framework based on the analysis of covariance (ANCOVA) to control the confounders (age, gender (male as the risk factor), prior colonoscopy experience, colonoscopy indication, and baseline constipation score). The results will be compared with the findings based on the per-protocol (PP) analysis as part of the sensitivity analysis. The protocol adheres to SPIRIT 2025 and the SPIRIT-AI extension guidelines to ensure comprehensive reporting of this AI-based intervention. This trial has received ethics approval and the trial protocol has been registered with the clinicaltrials.gov registry (NCT06905782).